首页> 外国专利> Treatment of diseases induced by L-dopa, dopamine agonists and / or dopamine activators

Treatment of diseases induced by L-dopa, dopamine agonists and / or dopamine activators

机译：治疗左旋多巴，多巴胺激动剂和/或多巴胺激活剂引起的疾病

页面导航

摘要
著录项
相似文献

摘要

One or more agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone or glycosylated forms thereof, including E and/or F ring opened derivatives thereof, is used to treat or prevent L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders, such as L-DOPA induced dyskinesia (LID), which is a side effect of L-DOPA, dopamine agonist and/or dopamine enhancer therapies, e.g., for Parkinson's disease. The agent according to the invention may be administered in association with the therapeutic agent for the treatment of the Parkinson's disease or another dopamine-responsive disorder.

机译：一种或多种选自A / B-顺式呋喃丁酮，呋喃丁烯，spirostane和spirostene甾体皂苷元及其酯，醚，酮或糖基化形式的试剂，包括其E和/或F开环衍生物，用于治疗或预防L- DOPA，多巴胺激动剂和/或多巴胺增强剂诱导的疾病，例如L-DOPA诱导的运动障碍（LID），这是L-DOPA，多巴胺激动剂和/或多巴胺增强剂疗法的副作用，例如用于帕金森氏病。本发明的药剂可以与用于治疗帕金森氏病或另一种多巴胺反应性疾病的治疗剂联合给药。

著录项

公开/公告号JP2013543482A

专利类型
公开/公告日2013-12-05

原文格式PDF
申请/专利权人ファイトファームピーエルシー;
展开▼

申请/专利号JP20130520218
发明设计人ハウスン;パトリックアレクサンダー;
展开▼

申请日2011-07-20
分类号A61K31/015;A61P43;A61K31/58;A61P9/02;A61P9/06;A61P1/08;A61P11;A61P25/20;A61P25;A61P25/30;A61P25/22;A61P25/18;A61P25/16;A61K38;A61K31/472;A61K31/48;A61K31/428;A61K31/4045;A61K45;C07K5/083;
国家 JP
入库时间 2022-08-21 16:13:23

相似文献

专利
外文文献
中文文献